Partner With Us NRI

Gujarat Themis Biosyn Ltd share Price Today

Company details

6M Return 18.07%
1Y Return 20.46%
Mkt Cap.(Cr) 276.78
Volume 52,423
Div Yield 0.57%
OI Chg %
Volume 52,423

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results:

  • Q4FY23:
    • Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22
    • EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%.
    • EBITDA Margin stood at 52.98%, up by 751 bps
    • Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22
    • EPS for the quarter stood at Rs 8.05
  • FY23:
    • Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71%
    • EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86%
    • EBITDA Margin stood at 49.82%
    • FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22
    • EPS for the year stood at Rs 39.90



Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Gujarat Themis Biosyn Ltd Stocks COMPARISION


Equity Capital: 149.14 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,819.21 39,849.27
LAST 3M 59,182.99 17,912.96
LAST 6M 101,166.54 92,564.27
LAST 12M 166,925.45 138,096.90

Gujarat Themis Biosyn Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Promoted by Kantilal Shah, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985. It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11.25 crores to Rs 11.60 crores after allotment of 350,000 Equity shares of Rs 10 each at a premium of Rs 20 per share to the financial institutions by way of conversion of fund interst term loan. During the year installed capacity of rifamysin-S was increased to 90 mtpa and expansion of rifampicin was achieved to the maximum capacity of 120 mtpa. It also commenced operations of its new pharmaceutical division and launched a wide range of anti-tuberculosis products and other antibiotics. The company is constantly identifying new areas for diversification and also capacity expansion of exisiting product in order to further reduction in cost of production and increase in turnover.

Registered Address

69/C GIDC Industrial Estate, Valsad Dist, VAPI, Gujarat, 396195

Tel : 91-260-2430027
Email : accounts:gtbl.co.in/gtblmumbai:gtbl.in
Website : http://www.gtbl.in

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 506879
Book Closure Date (Month) :
BSE Group : B
ISIN : INE942C01045

FAQ’s on Gujarat Themis Biosyn Ltd Shares

You can buy Gujarat Themis Biosyn Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Gujarat Themis Biosyn Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 08, 2023 04:01 PM the closing price of Gujarat Themis Biosyn Ltd was ₹ 190.50.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 08, 2023 04:01 PM, the market cap of Gujarat Themis Biosyn Ltd stood at ₹ 276.78.

The latest PE ratio of Gujarat Themis Biosyn Ltd as of Dec 08, 2023 04:01 PM is 26.48

The latest PB ratio of Gujarat Themis Biosyn Ltd as of Dec 08, 2023 04:01 PM is 0.13

The 52-week high of Gujarat Themis Biosyn Ltd is ₹ 228.95 while the 52-week low is ₹ 114.42

Download Our App

market app
market app